C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.